The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars to Raise Unique Questions

Biosimilars to Raise Unique Questions

February 16, 2017 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists are accustomed to educating patients about medications, but biologic medications—and now biosimilars—require some additional time and discussion.

You Might Also Like
  • Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety
  • Biosimilars: Unanswered Questions
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
Also By This Author
  • Lupus Immunology Findings Provide Insights for Rheumatologists

“Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The first FDA-approved biosimilar to become available in the U.S. is Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab). Thus, patient awareness of biosimilar drugs is not commonplace yet. However, that will likely change in the future as more biosimilars are approved for use.

“Patients are likely to start having questions about biosimilars just as rheumatologists started asking questions a few years ago in anticipation of their arrival,” says Dr. Huston. Patient questions that will likely arise about biosimilars—and possible answers—include:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What is a biosimilar?
Possible answer: The U.S. Food and Drug Administration (FDA) says, “A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product.”

Are biosimilars generic versions of biologics?
Possible answer: No, they are not the same. “Biosimilars are not generics, which are ‘replicas’ of the branded drug,” says Ellen Field, MD, Lehigh Valley Health Network, Bethlehem, Pa.

Dr. Huston explains that biologics and biosimilars are large, complex molecules created in living systems. “Their effectiveness and safety are directly related to their three-dimensional structure, which can be altered by many factors in the manufacturing process,” he says. “It is, therefore, impossible to make an exact copy of a biologic drug, unlike the situation for traditional generics, which are much simpler from a chemistry perspective.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Is a biosimilar as safe and effective as the reference compound?
Possible answer: The FDA has approved biosimilar drugs, and will likely approve more, because they are believed to be safe and effective. Research is ongoing. Dr. Field says, “I believe the rheumatology community is willing to consider biosimilars for their patients if studies substantiate the safety and efficacy profiles are very similar to the parent compound and [if the biosimilar] is the best treatment option for them and their lifestyle.”

Rheumatologists want to have confidence telling patients it is okay to take a biosimilar, but most are opposed to mandatory medication switching of stable patients by insurance companies or pharmacies, Dr. Huston says. This could become an issue if insurance companies advocate switching medications or if patients are looking to change from a biologic to a biosimilar due to cost.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars Tagged With: biologic, biosimilar, FDA, Inflectra, Remicade

You Might Also Like:
  • Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety
  • Biosimilars: Unanswered Questions
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
  • The Science Behind Biosimilars

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.